Design innovations and baseline findings in a long‐term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long‐Term Study–1
Identifieur interne : 000607 ( Istex/Corpus ); précédent : 000606; suivant : 000608Design innovations and baseline findings in a long‐term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long‐Term Study–1
Auteurs : Jordan J. ElmSource :
- Movement Disorders [ 0885-3185 ] ; 2012-10.
English descriptors
Abstract
Based on the preclinical data and the results of a phase II futility study, creatine was selected for an efficacy trial in Parkinson's disease (PD). We present the design rationale and a description of the study cohort at baseline. A randomized, multicenter, double‐blind, parallel‐group, placebo‐controlled phase III study of creatine (10 g daily) in participants with early, treated PD, the Long‐term Study–1 (LS‐1), is being conducted by the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease network. The study utilizes a global statistical test (GST) encompassing five clinical rating scales to provide a multidimensional assessment of disease progression. A total of 1,741 PD participants from 45 sites in the United States and Canada were randomized 1:1 to either 10 g of creatine/day or matching placebo. Participants are being evaluated for a minimum of 5 years. The LS‐1 baseline cohort includes participants treated with dopaminergic therapy and generally mild PD. LS‐1 represents the largest cohort of patients with early treated PD ever enrolled in a clinical trial. The GST approach should provide high power to test the hypothesis that daily administration of creatine (10 g/day) is more effective than placebo in slowing clinical decline in PD between baseline and the 5‐year follow‐up visit against the background of dopaminergic therapy and best PD care. © 2012 Movement Disorder Society
Url:
DOI: 10.1002/mds.25175
Links to Exploration step
ISTEX:959231ADE32D28779E411441F7FD5198E63C15C5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Design innovations and baseline findings in a long‐term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long‐Term Study–1</title><author><name sortKey="Elm, Jordan J" sort="Elm, Jordan J" uniqKey="Elm J" first="Jordan J." last="Elm">Jordan J. Elm</name><affiliation><mods:affiliation>Division of Biostatistics and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Suite 303, P.O. Box 250835, Charleston, SC 29425, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Biostatistics and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Suite 303, P.O. Box 250835, Charleston, SC 29425, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:959231ADE32D28779E411441F7FD5198E63C15C5</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1002/mds.25175</idno><idno type="url">https://api-v5.istex.fr/document/959231ADE32D28779E411441F7FD5198E63C15C5/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000607</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000607</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Design innovations and baseline findings in a long‐term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long‐Term Study–1</title><author><name sortKey="Elm, Jordan J" sort="Elm, Jordan J" uniqKey="Elm J" first="Jordan J." last="Elm">Jordan J. Elm</name><affiliation><mods:affiliation>Division of Biostatistics and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Suite 303, P.O. Box 250835, Charleston, SC 29425, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Biostatistics and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Suite 303, P.O. Box 250835, Charleston, SC 29425, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-10">2012-10</date><biblScope unit="volume">27</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1513">1513</biblScope><biblScope unit="page" to="1521">1521</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">959231ADE32D28779E411441F7FD5198E63C15C5</idno><idno type="DOI">10.1002/mds.25175</idno><idno type="ArticleID">MDS25175</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>clinical trial</term><term>creatine</term><term>global statistical test</term><term>neuroprotection</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Based on the preclinical data and the results of a phase II futility study, creatine was selected for an efficacy trial in Parkinson's disease (PD). We present the design rationale and a description of the study cohort at baseline. A randomized, multicenter, double‐blind, parallel‐group, placebo‐controlled phase III study of creatine (10 g daily) in participants with early, treated PD, the Long‐term Study–1 (LS‐1), is being conducted by the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease network. The study utilizes a global statistical test (GST) encompassing five clinical rating scales to provide a multidimensional assessment of disease progression. A total of 1,741 PD participants from 45 sites in the United States and Canada were randomized 1:1 to either 10 g of creatine/day or matching placebo. Participants are being evaluated for a minimum of 5 years. The LS‐1 baseline cohort includes participants treated with dopaminergic therapy and generally mild PD. LS‐1 represents the largest cohort of patients with early treated PD ever enrolled in a clinical trial. The GST approach should provide high power to test the hypothesis that daily administration of creatine (10 g/day) is more effective than placebo in slowing clinical decline in PD between baseline and the 5‐year follow‐up visit against the background of dopaminergic therapy and best PD care. © 2012 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Jordan J. Elm</name><affiliations><json:string>Division of Biostatistics and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Suite 303, P.O. Box 250835, Charleston, SC 29425, USA</json:string><json:string>Division of Biostatistics and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Suite 303, P.O. Box 250835, Charleston, SC 29425, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>neuroprotection</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clinical trial</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>creatine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>global statistical test</value></json:item></subject><articleId><json:string>MDS25175</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Based on the preclinical data and the results of a phase II futility study, creatine was selected for an efficacy trial in Parkinson's disease (PD). We present the design rationale and a description of the study cohort at baseline. A randomized, multicenter, double‐blind, parallel‐group, placebo‐controlled phase III study of creatine (10 g daily) in participants with early, treated PD, the Long‐term Study–1 (LS‐1), is being conducted by the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease network. The study utilizes a global statistical test (GST) encompassing five clinical rating scales to provide a multidimensional assessment of disease progression. A total of 1,741 PD participants from 45 sites in the United States and Canada were randomized 1:1 to either 10 g of creatine/day or matching placebo. Participants are being evaluated for a minimum of 5 years. The LS‐1 baseline cohort includes participants treated with dopaminergic therapy and generally mild PD. LS‐1 represents the largest cohort of patients with early treated PD ever enrolled in a clinical trial. The GST approach should provide high power to test the hypothesis that daily administration of creatine (10 g/day) is more effective than placebo in slowing clinical decline in PD between baseline and the 5‐year follow‐up visit against the background of dopaminergic therapy and best PD care. © 2012 Movement Disorder Society</abstract><qualityIndicators><score>8.152</score><pdfVersion>1.4</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1452</abstractCharCount><pdfWordCount>7156</pdfWordCount><pdfCharCount>46991</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>221</abstractWordCount></qualityIndicators><title>Design innovations and baseline findings in a long‐term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long‐Term Study–1</title><corporate><json:item><name>The NINDS NET‐PD Investigators</name></json:item></corporate><genre><json:string>article</json:string></genre><host><title>Movement Disorders</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi><issn><json:string>0885-3185</json:string></issn><eissn><json:string>1531-8257</json:string></eissn><publisherId><json:string>MDS</json:string></publisherId><volume>27</volume><issue>12</issue><pages><first>1513</first><last>1521</last><total>9</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Research Article</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string></inist></categories><publicationDate>2012</publicationDate><copyrightDate>2012</copyrightDate><doi><json:string>10.1002/mds.25175</json:string></doi><id>959231ADE32D28779E411441F7FD5198E63C15C5</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/959231ADE32D28779E411441F7FD5198E63C15C5/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/959231ADE32D28779E411441F7FD5198E63C15C5/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api-v5.istex.fr/document/959231ADE32D28779E411441F7FD5198E63C15C5/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Design innovations and baseline findings in a long‐term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long‐Term Study–1</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Copyright © 2012 Movement Disorder Society</p></availability><date>2012</date></publicationStmt><notesStmt><note type="content">*Funding agencies: This study was sponsored by the National Institutes of Health, National Institute of Neurological Disorders and Stroke.</note><note type="content">*Relevant conflicts of interest/financial disclosure: Nothing to report.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Design innovations and baseline findings in a long‐term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long‐Term Study–1</title><author><orgName>The NINDS NET‐PD Investigators</orgName></author><author xml:id="author-1"><persName><forename type="first">Jordan J.</forename><surname>Elm</surname></persName><affiliation>Division of Biostatistics and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Suite 303, P.O. Box 250835, Charleston, SC 29425, USA</affiliation><affiliation>Division of Biostatistics and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Suite 303, P.O. Box 250835, Charleston, SC 29425, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-10"></date><biblScope unit="volume">27</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1513">1513</biblScope><biblScope unit="page" to="1521">1521</biblScope></imprint></monogr><idno type="istex">959231ADE32D28779E411441F7FD5198E63C15C5</idno><idno type="DOI">10.1002/mds.25175</idno><idno type="ArticleID">MDS25175</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2012</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Based on the preclinical data and the results of a phase II futility study, creatine was selected for an efficacy trial in Parkinson's disease (PD). We present the design rationale and a description of the study cohort at baseline. A randomized, multicenter, double‐blind, parallel‐group, placebo‐controlled phase III study of creatine (10 g daily) in participants with early, treated PD, the Long‐term Study–1 (LS‐1), is being conducted by the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease network. The study utilizes a global statistical test (GST) encompassing five clinical rating scales to provide a multidimensional assessment of disease progression. A total of 1,741 PD participants from 45 sites in the United States and Canada were randomized 1:1 to either 10 g of creatine/day or matching placebo. Participants are being evaluated for a minimum of 5 years. The LS‐1 baseline cohort includes participants treated with dopaminergic therapy and generally mild PD. LS‐1 represents the largest cohort of patients with early treated PD ever enrolled in a clinical trial. The GST approach should provide high power to test the hypothesis that daily administration of creatine (10 g/day) is more effective than placebo in slowing clinical decline in PD between baseline and the 5‐year follow‐up visit against the background of dopaminergic therapy and best PD care. © 2012 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>neuroprotection</term></item><item><term>Parkinson's disease</term></item><item><term>clinical trial</term></item><item><term>creatine</term></item><item><term>global statistical test</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2012-02-14">Received</change><change when="2012-07-31">Registration</change><change when="2012-10">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/959231ADE32D28779E411441F7FD5198E63C15C5/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="120"><doi origin="wiley" registered="yes">10.1002/mds.v27.12</doi><numberingGroup><numbering type="journalVolume" number="27">27</numbering><numbering type="journalIssue">12</numbering></numberingGroup><coverDate startDate="2012-10">October 2012</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="110" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.25175</doi><idGroup><id type="unit" value="MDS25175"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2012 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2012-02-14"></event><event type="manuscriptRevised" date="2012-06-19"></event><event type="manuscriptAccepted" date="2012-07-31"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.1.9 mode:FullText" date="2012-10-18"></event><event type="firstOnline" date="2012-10-18"></event><event type="publishedOnlineFinalForm" date="2012-10-18"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.3.4 mode:FullText" date="2015-02-24"></event></eventGroup><numberingGroup><numbering type="pageFirst">1513</numbering><numbering type="pageLast">1521</numbering></numberingGroup><correspondenceTo>Division of Biostatistics and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Suite 303, P.O. Box 250835, Charleston, SC 29425, USA</correspondenceTo><objectNameGroup><objectName elementName="appendix">Appendix</objectName></objectNameGroup><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS25175.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="5"></count><count type="referenceTotal" number="52"></count><count type="wordTotal" number="11248"></count></countGroup><titleGroup><title type="main" xml:lang="en">Design innovations and baseline findings in a long‐term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long‐Term Study–1<link href="#fn1"></link><link href="#fn2"></link><link href="#fn3"></link></title><title type="short" xml:lang="en">LS‐1 Design and Baseline Findings</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Jordan J.</givenNames><familyName>Elm</familyName></personName><contactDetails><email>elmj@musc.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author"><groupName>The NINDS NET‐PD Investigators</groupName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Division of Biostatistics and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Suite 303, P.O. Box 250835, Charleston, SC 29425, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">neuroprotection</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">clinical trial</keyword><keyword xml:id="kwd4">creatine</keyword><keyword xml:id="kwd5">global statistical test</keyword></keywordGroup><supportingInformation><p> Additional Supporting Information may be found in the online version of this article. </p><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds25175:MDS_25175_sm_SuppTab1"></mediaResource><caption>Supporting Information</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Based on the preclinical data and the results of a phase II futility study, creatine was selected for an efficacy trial in Parkinson's disease (PD). We present the design rationale and a description of the study cohort at baseline. A randomized, multicenter, double‐blind, parallel‐group, placebo‐controlled phase III study of creatine (10 g daily) in participants with early, treated PD, the Long‐term Study–1 (LS‐1), is being conducted by the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease network. The study utilizes a global statistical test (GST) encompassing five clinical rating scales to provide a multidimensional assessment of disease progression. A total of 1,741 PD participants from 45 sites in the United States and Canada were randomized 1:1 to either 10 g of creatine/day or matching placebo. Participants are being evaluated for a minimum of 5 years. The LS‐1 baseline cohort includes participants treated with dopaminergic therapy and generally mild PD. LS‐1 represents the largest cohort of patients with early treated PD ever enrolled in a clinical trial. The GST approach should provide high power to test the hypothesis that daily administration of creatine (10 g/day) is more effective than placebo in slowing clinical decline in PD between baseline and the 5‐year follow‐up visit against the background of dopaminergic therapy and best PD care. © 2012 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p><b>Funding agencies:</b> This study was sponsored by the National Institutes of Health, National Institute of Neurological Disorders and Stroke.</p></note><note xml:id="fn2"><p><b>Relevant conflicts of interest/financial disclosure:</b> Nothing to report.</p></note><note xml:id="fn3"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Design innovations and baseline findings in a long‐term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long‐Term Study–1</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>LS‐1 Design and Baseline Findings</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Design innovations and baseline findings in a long‐term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long‐Term Study–1</title></titleInfo><name type="personal"><namePart type="given">Jordan J.</namePart><namePart type="family">Elm</namePart><affiliation>Division of Biostatistics and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Suite 303, P.O. Box 250835, Charleston, SC 29425, USA</affiliation><affiliation>Division of Biostatistics and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Suite 303, P.O. Box 250835, Charleston, SC 29425, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>The NINDS NET‐PD Investigators</namePart><description>Division of Biostatistics and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Suite 303, P.O. Box 250835, Charleston, SC 29425, USA</description></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2012-10</dateIssued><dateCaptured encoding="w3cdtf">2012-02-14</dateCaptured><dateValid encoding="w3cdtf">2012-07-31</dateValid><copyrightDate encoding="w3cdtf">2012</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">5</extent><extent unit="references">52</extent><extent unit="words">11248</extent></physicalDescription><abstract lang="en">Based on the preclinical data and the results of a phase II futility study, creatine was selected for an efficacy trial in Parkinson's disease (PD). We present the design rationale and a description of the study cohort at baseline. A randomized, multicenter, double‐blind, parallel‐group, placebo‐controlled phase III study of creatine (10 g daily) in participants with early, treated PD, the Long‐term Study–1 (LS‐1), is being conducted by the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease network. The study utilizes a global statistical test (GST) encompassing five clinical rating scales to provide a multidimensional assessment of disease progression. A total of 1,741 PD participants from 45 sites in the United States and Canada were randomized 1:1 to either 10 g of creatine/day or matching placebo. Participants are being evaluated for a minimum of 5 years. The LS‐1 baseline cohort includes participants treated with dopaminergic therapy and generally mild PD. LS‐1 represents the largest cohort of patients with early treated PD ever enrolled in a clinical trial. The GST approach should provide high power to test the hypothesis that daily administration of creatine (10 g/day) is more effective than placebo in slowing clinical decline in PD between baseline and the 5‐year follow‐up visit against the background of dopaminergic therapy and best PD care. © 2012 Movement Disorder Society</abstract><note type="content">*Funding agencies: This study was sponsored by the National Institutes of Health, National Institute of Neurological Disorders and Stroke.</note><note type="content">*Relevant conflicts of interest/financial disclosure: Nothing to report.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>keywords</genre><topic>neuroprotection</topic><topic>Parkinson's disease</topic><topic>clinical trial</topic><topic>creatine</topic><topic>global statistical test</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="journal">journal</genre><note type="content"> Additional Supporting Information may be found in the online version of this article.Supporting Info Item: Supporting Information - </note><subject><genre>article-category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>1513</start><end>1521</end><total>9</total></extent></part></relatedItem><identifier type="istex">959231ADE32D28779E411441F7FD5198E63C15C5</identifier><identifier type="DOI">10.1002/mds.25175</identifier><identifier type="ArticleID">MDS25175</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2012 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000607 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000607 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:959231ADE32D28779E411441F7FD5198E63C15C5
|texte= Design innovations and baseline findings in a long‐term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long‐Term Study–1
}}
| This area was generated with Dilib version V0.6.29. |  |